Heron Therapeutics Inc (HRTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heron Therapeutics Inc (HRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012212
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused therapeutic products for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company’s first commercial product Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Heron’s developmental pipeline includes HTX-011 for post-operative pain management and Cinvanti (HTX-019) for chemotherapy-induced nausea and vomiting (CINV) prevention. Heron is headquartered in San Diego, California, the US.

Heron Therapeutics Inc (HRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heron Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 12
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 14
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 16
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 18
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 20
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 21
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 23
A.P. Pharma Completes Private Placement Of Units For US$24 Million 24
Debt Offering 25
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For US$1.5 Million 25
Heron Therapeutics Inc – Key Competitors 26
Heron Therapeutics Inc – Key Employees 27
Heron Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2017: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 29
Aug 09, 2017: Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 30
May 10, 2017: Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 31
Feb 23, 2017: Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress 32
Nov 08, 2016: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress 33
Aug 08, 2016: Heron Therapeutics Reports Second Quarter 2016 Financial Results and Recent Corporate Progress 34
May 05, 2016: Heron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress 35
Feb 19, 2016: Heron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress 36
Corporate Communications 37
Apr 24, 2017: Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance 37
Jun 22, 2016: Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors 38
Clinical Trials 39
Jan 04, 2017: Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty 39
Jan 04, 2017: Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies 40
Sep 08, 2016: Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek 2016 41
Aug 29, 2016: Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek 2016 43
Aug 01, 2016: Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heron Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Heron Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 12
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 14
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 16
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 18
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 20
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 21
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 23
A.P. Pharma Completes Private Placement Of Units For US$24 Million 24
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For US$1.5 Million 25
Heron Therapeutics Inc, Key Competitors 26
Heron Therapeutics Inc, Key Employees 27
Heron Therapeutics Inc, Other Locations 28

★海外企業調査レポート[Heron Therapeutics Inc (HRTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sharjah Insurance Company P.S.C.:企業の戦略・SWOT・財務情報
    Sharjah Insurance Company P.S.C. - Strategy, SWOT and Corporate Finance Report Summary Sharjah Insurance Company P.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Servest Group Ltd:企業の戦略的SWOT分析
    Servest Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • GS Engineering & Construction Corp (006360):企業の財務・戦略的SWOT分析
    GS Engineering & Construction Corp (006360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • SMCP S.A.S (SMCP):企業の財務・戦略的SWOT分析
    SMCP S.A.S (SMCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • IXICO Plc (IXI):医療機器:M&Aディール及び事業提携情報
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs. The company offers products such as assessa, trial tracker, trialwire and mehealth. It provides web-based …
  • Gujarat State Electricity Corp Ltd:企業の戦略的SWOT分析
    Gujarat State Electricity Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Tenaska Energy, Inc.:企業の戦略・SWOT・財務情報
    Tenaska Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tenaska Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kuwait Food Company (Americana) KSCP:企業の戦略的SWOT分析
    Kuwait Food Company (Americana) KSCP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Venus Remedies Ltd (VENUSREM):製薬・医療:M&Aディール及び事業提携情報
    Summary Venus Remedies Ltd (Venus) is a pharmaceutical company that develops, manufactures and commercializes research, herbal and generic products. The company’s manufactures products for analgesic and antipyretic, antibiotic, anticoagulant, disinfectant and antiseptic, iron supplement, neurology, …
  • Hankyu Hanshin Holdings, Inc.:企業の戦略・SWOT・財務情報
    Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Versantis AG-製薬・医療分野:企業M&A・提携分析
    Summary Versantis AG (Versantis), is a preclinical stage pharmaceutical company which offers new medicines and diagnostics for treating liver diseases. It’s lead pipeline product VS-01, capable of removing toxic agents from the organism and save patients from prescription and illicit drug overdoses. …
  • Transmetro Corporation Limited
    Transmetro Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Transmetro Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報
    Summary Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique …
  • BOOM Logistics Ltd (BOL):企業の財務・戦略的SWOT分析
    BOOM Logistics Ltd (BOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sahara Petrochemicals Co:企業の戦略的SWOT分析
    Sahara Petrochemicals Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Marathon Petroleum Corporation:企業の戦略・SWOT・財務情報
    Marathon Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Marathon Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • MAEC-Kazatomprom LLP:企業の戦略的SWOT分析
    MAEC-Kazatomprom LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Amcor Limited:企業の戦略・SWOT・財務情報
    Amcor Limited - Strategy, SWOT and Corporate Finance Report Summary Amcor Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Applied Medical Resources Corporation:企業の戦略的SWOT分析
    Applied Medical Resources Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • CACI International Inc. (CACI):企業の戦略的SWOT分析
    CACI International Inc. (CACI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆